日本的質子治療市場:各產品類型，各適應症，各設定類型，各終端用戶，各地區，機會，預測，2018年～2032年

日本質子治療市場規模預計將在 2025 年至 2032 年期間以 8.20% 的複合年增長率增長，從 2024 年的 8116 萬美元增至 2032 年的 1.5247 億美元。日本質子治療市場受到多種因素的影響，例如醫療支出增加、醫生對先進治療的偏好增加以及癌症發生率上升。日本是世界上質子治療設施數量領先的國家之一，尖端放射治療技術的增加和持續的技術進步進一步推動了市場的發展。醫療專業人士和廣大民眾對晚期癌症治療的認識不斷提高也是該市場的主要動力。

日本的癌症發生率正穩定上升，對先進治療的需求也日益增加。日本國立癌症中心和國立癌症研究開發機構預測，2024年日本癌症病例數將達到97.93萬例，令人擔憂。為了應對這項課題，日本一直走在醫療技術的前沿，發現了質子束治療等新治療方法。這種高度針對性的治療方法旨在治療腫瘤，同時保護周圍的健康組織，因此是理想的選擇。雖然許多專門的中心已經實施了這項技術，但日益加重的癌症負擔正在進一步推動對質子治療的需求。

日本一直致力於讓盡可能多的人能夠獲得尖端的癌症治療。日本的全民健康保險制度使患者自付費用保持在較低水平，並提供全面的醫療服務。 2024年6月，日本厚生勞動省宣布，肺癌早期質子束治療將納入國民健康保險涵蓋範圍，引起廣泛關注。這項突破性的舉措為許多人提供了更多的復健選擇。這將為患者提供先進的質子治療，同時鞏固日本在對抗癌症方面致力於創新和公平的決心。

本報告提供日本的質子治療市場相關調查，提供市場概要，以及各產品類型，各適應症，各設定類型，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 日本的質子治療市場預測，2018年～2032年

• 市場規模的分析與預測
• 市場佔有率分析與預測
• 市場地圖分析，2024年
  • 各產品類型
  • 各適應症
  • 各設定類型
  • 各終端用戶
  • 各地區

第5章 需求供給分析

第6章 進出口的分析

第7章 價值鏈分析

第8章 波特的五力分析

第9章 大環境分析

第10章 價格分析

第11章 市場動態

第12章 市場趨勢與發展

第13章 法規結構和革新

第14章 專利的形勢

第15章 案例研究

第16章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 市場主要加入企業前五名的形勢
  • Hitachi High-Tech Corporation
  • Sumitomo Heavy Industries, Ltd.
  • Varian Medical Systems, Inc.
  • Toshiba Energy Systems & Solutions Corporation
  • Ion Beam Applications SA (IBA)
  • Elekta Co., Ltd
  • Mitsubishi Electric Corporation
  • Mevion Medical Systems, Inc.
  • B dot Medical Inc.
  • ProTom International

第17章 策略性建議

第18章 關於調查公司·免責聲明

Japan proton therapy market is predicted to grow at a CAGR of 8.20% between FY2025 to FY2032, rising from USD 81.16 million in FY2024 to USD 152.47 million by FY2032. The proton therapy market in Japan is influenced by several factors, including rising expenditure on health, a growing trend toward advanced treatment among physicians, and a growing incidence of cancer. Japan is among the world's leading countries in the number of proton therapy facilities, with increased state-of-the-art radiotherapy technology and continued technological advancements further driving the market. Increased awareness among healthcare professionals and the population as a whole of advanced cancer treatment is also a key driver for this market.

The cancer incidence in Japan has been rising steadily, which has resulted in an ever-growing need for advanced treatment. The National Cancer Center and National Research and Development Agency of Japan projected that, in 2024, there were 979,300 cancer incidences in the country, reflecting a cause for concern. To address this challenge, Japan has been at the forefront of medical technology, having discovered new treatments like proton therapy. This highly targeted intervention is designed to treat tumors while sparing surrounding healthy tissues, thus making it a preferred choice. With many specialized centers already having this technology, the increasing burden of cancer is further fueling the demand for proton therapy, which provides better treatment outcomes and is a demonstration of Japan's leadership in sophisticated cancer treatment.

Japan has been striving to make cutting-edge cancer care more available to the public. Japan's universal public health insurance ensures that a comprehensive range of medical care is made accessible, keeping patients' out-of-pocket expenses low. In June 2024, Japan's Ministry of Health, Labour, and Welfare made headlines by announcing that early lung cancer proton therapy would be covered by national health insurance. This groundbreaking move encourages a curative option for many. It enables patients to take advantage of advanced proton therapy while cementing Japan's dedication to innovation and equity in the fight against cancer.

Advancements in Cancer Treatment Impacting Japan Proton Therapy Market

Japan is at the forefront of creating novel cancer treatments by utilizing cutting-edge technologies including immunotherapy, AI-powered diagnostics, and personalized medicine. Proton therapy is one of the remarkable advancements, giving precise radiation with less harm to the surrounding healthy tissues, and best suited for pediatric and persistent cancers. Japan has made substantial investments in the expansion of several proton therapy centers, owing to an increase in cancer incidence and government support. Some of the innovations in cancer treatment, such as flash therapy and miniaturized proton systems, are reducing its cost and increasing its efficiency. Several companies have collaborated with universities to innovate and improve cancer care innovations. Sumitomo Heavy Industries Ltd. and Fujita Health University collaborated and initiated research for a new BNCT and an extremely powerful new cancer drug in December 2024. These developments can cure presently incurable cancers such as pancreatic cancer. This technology is changing the way treatments are done in cancer and presenting huge market expansion opportunities for proton treatment in Japan, making it a pioneer for cancer treatment breakthroughs. This partnership creates new opportunities for growth and innovation in the sector. These advancements, coupled with the growing need for minimally invasive treatments, are fueling the expansion of Japan's proton therapy market, drawing domestic and foreign investments. Through additional research, Japan will be able to position itself at the forefront of future cancer therapies and take its rightful position in oncology treatment innovations globally.

Higher Adoption Supports Market Expansion

Japan is accelerating the adoption of advanced therapies owing to increased investments in its healthcare facilities. This new paradigm presents promising opportunities for proton therapy in Japan, with advanced treatments increasingly used in the clinic. With rising adoption in government and private cancer institutes, proton therapy is gaining traction in the Japanese cancer treatment industry. Chubu International Medical Center launched its "Proton Beam Therapy Department" in March 2024 as a pioneer in cancer treatment. The center, being Japan's first to use Varian's newest "ProBeam" technology, will subsequently introduce Boron Neutron Capture Therapy (BNCT). The technology is backing the growing demand for proton therapy in Japan, propelling the market's growth and calling for continuous innovations to meet the evolving requirements of medical professionals. Studies are ongoing to improve its use, pushing its application into paediatrics, head and neck, and other recurrent cancers. While the need for targeted and minimally invasive treatments increases, Japan is becoming the world leader in proton therapy technology, which is defining the future of cancer care.

Hospitals are the Major End-users of the Proton Therapy in Japan

Hospitals are the most crucial players in the Japanese proton therapy market, and they are the major end-users of this novel cancer treatment. Large hospitals have been the forerunners in adopting this technology in their cancer departments because proton therapy centers cost a lot of money to establish. They also facilitate research and innovation. For instance, in January 2025, the Tokyo Metropolitan Hospital Organization invested USD 121 million (5 billion yen) in establishing a proton beam therapy center at Komagome Hospital in Tokyo, Japan. The center will begin treating patients in fiscal 2030. This indicates that Japanese hospitals are significant consumers of this innovative treatment. The rising incidence of cancer, along with government encouragement of new treatment, has also strengthened their position. Moreover, partnering with research centers facilitates the development of new technologies and makes treatment easily available to patients. With more emphasis on precision medicine, hospitals continue to expand their proton therapy services, making them significant contributors to market growth and development.

Future Market Scenario (FY2025 -FY2032F)

Japan's proton therapy market will grow strongly with enhanced precision oncology, rising cancer cases, and strong government backing. Rising investments in new radiation technology and expanding healthcare infrastructure further augment growth. The high cost of treatment and restricted reimbursement, however, remains a challenge. Nevertheless, the market is projected to thrive with enhanced awareness and accessibility, further solidifying Japan in advanced cancer therapy.

In June 2023, B dot Medical Inc. formed a strategic partnership with RaySearch Laboratories AB to advance proton therapy by integrating RayStation and RayCare with B dot Medical's ultra-compact proton therapy system. The collaboration intends to make proton therapy more accessible to healthcare professionals to treat more patients. This partnership fosters market expansion and encourages widespread adoption of proton therapy by maximizing system capabilities and providing advanced solutions. Furthermore, it contributes to advancing radiation oncology and achieving the mission of 'proton for everyone'.

Key Players Landscape and Outlook

Japan's proton therapy market players follow various strategies to strengthen their market reach. They focus on getting regulatory approvals to facilitate ease of product entry and compliance. Strategic partnerships with medical institutions and technology companies accelerate innovation and access. Increasing treatment centers, maximizing patient financing options, and research expenditures further deepen their hold. All these strategies together encourage greater adoption and long-term growth in Japan's proton therapy market.

In November 2023, B dot Medical Inc. got approval from the Ministry of Health, Labour and Welfare of Japan for their ultra-compact proton therapy system Phemto, as per the Pharmaceuticals and Medical Devices Act. Phemto is an innovative device, which has a vision of being as tiny as X-ray (LINAC) therapy systems. This clearance reinforces B dot Medical's market position, reflecting its innovation and dedication to making advanced proton therapy easily available to healthcare facilities. Their achievement is evidence of their dedication to revolutionizing radiation oncology.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Proton Therapy Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product Type
    • 4.2.1.1. Systems
      • 4.2.1.1.1. Cyclotron
      • 4.2.1.1.2. Synchrotron
      • 4.2.1.1.3. Synchrocyclotron
    • 4.2.1.2. Services
  • 4.2.2. By Indications
    • 4.2.2.1. Head and Neck Cancer
    • 4.2.2.2. Central Nervous System Cancer
    • 4.2.2.3. Prostate Cancer
    • 4.2.2.4. Breast Cancer
    • 4.2.2.5. Lung Cancer
    • 4.2.2.6. Pediatric Cancer
    • 4.2.2.7. Gastrointestinal Cancer
    • 4.2.2.8. Others
  • 4.2.3. By Setup Type
    • 4.2.3.1. Single-Room Systems
    • 4.2.3.2. Multi-Room Systems
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Proton Therapy Centers
    • 4.2.4.3. Cancer Centers or Institutes
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Product Type
  • 4.3.2. By Indications
  • 4.3.3. By Setup Type
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Developments and Innovations

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 5 Market Players
  • 16.3.1. Hitachi High-Tech Corporation
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Sumitomo Heavy Industries, Ltd.
  • 16.3.3. Varian Medical Systems, Inc.
  • 16.3.4. Toshiba Energy Systems & Solutions Corporation
  • 16.3.5. Ion Beam Applications SA (IBA)
  • 16.3.6. Elekta Co., Ltd
  • 16.3.7. Mitsubishi Electric Corporation
  • 16.3.8. Mevion Medical Systems, Inc.
  • 16.3.9. B dot Medical Inc.
  • 16.3.10. ProTom International

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Proton Therapy Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. Japan Proton Therapy Market, By Volume, In Million Units, FY2018-FY2032F
• Figure 3. Japan Proton Therapy Market Share (%), By Product Type, FY2018-FY2032F
• Figure 4. Japan Proton Therapy Market Share (%), By Indications, FY2018-FY2032F
• Figure 5. Japan Proton Therapy Market Share (%), By Setup Type, FY2018-FY2032F
• Figure 6. Japan Proton Therapy Market Share (%), By End-user, FY2018-FY2032F
• Figure 7. Japan Proton Therapy Market Share (%), By Region, FY2018-FY2032F
• Figure 8. By Product Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 9. By Indications Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 10. By Setup Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 11. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 12. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024